XML 15 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTERESTS AND SHAREHOLDERS' EQUITY - USD ($)
$ in Millions
Total
Total Shareholders' Equity Attributable to Bruker Corporation
Common Stock
Treasury Stock
Additional Paid-In Capital
Retained Earnings
Accumulated Other Comprehensive (Loss) Income, Net of tax
Noncontrolling Interests in Consolidated Subsidiaries
Redeemable Noncontrolling Interests
Balance at beginning of period at Dec. 31, 2022 $ 1,125.7 $ 1,113.8 $ 1.7 $ (1,085.0) $ 256.3 $ 1,926.0 $ 14.8 $ 11.9 $ 6.1
Balance (in shares) at Dec. 31, 2022     147,023,144 28,366,442          
Increase (Decrease) in Stockholders' Equity                  
Stock options exercised 0.7 0.7     0.7        
Stock options exercised (in shares)     34,957            
Restricted Stock units vested (0.1) (0.1)     (0.1)        
Restricted Stock units vested (in shares)     18,463            
Stock based compensation 4.1 4.1     4.1        
Employee stock purchase plan 0.2 0.2     0.2        
Shares Repurchased (22.3) (22.3)   $ (22.2) (0.1)        
Shares Repurchased (in shares)     (315,318) 315,318          
Cash dividends declared and paid to common shareholders (7.4) (7.4)       (7.4)      
Biognosys acquisition - other shareholders                 2.3
Other shareholders of majority-owned acquisitions                 3.6
Proceeds from the sale of noncontrolling interests 5.3             5.3  
Consolidated net (loss) income 77.5 76.5       76.5   1.0 (0.1)
Other comprehensive income (loss) 15.1 14.8         14.8 0.3 0.1
Balance at end of period at Mar. 31, 2023 1,198.8 1,180.3 $ 1.7 $ (1,107.2) 261.1 1,995.1 29.6 18.5 12.0
Balance ending (in shares) at Mar. 31, 2023     146,761,246 28,681,760          
Increase (Decrease) in Stockholders' Equity                  
Stock options exercised 0.5 0.5     0.5        
Stock options exercised (in shares)     26,265            
Restricted Stock units vested (in shares)     2,897            
Stock based compensation 4.1 4.1     4.1        
Employee stock purchase plan 1.8 1.8     1.8        
Employee Stock Purchase Plan (in shares)     26,667            
Cash dividends declared and paid to common shareholders (7.4) (7.4)       (7.4)      
Loans to noncontrolling interest (0.3)             (0.3)  
Biognosys acquisition - other shareholders                 0.2
Consolidated net (loss) income 58.2 57.1       57.1   1.1 (0.4)
Other comprehensive income (loss) (5.0) (5.2)         (5.2) 0.2 0.1
Balance at end of period at Jun. 30, 2023 1,250.7 1,231.2 $ 1.7 $ (1,107.2) 267.5 2,044.8 24.4 19.5 11.9
Balance ending (in shares) at Jun. 30, 2023     146,817,075 28,681,760          
Balance at beginning of period at Dec. 31, 2023 1,394.6 1,377.2 $ 1.7 $ (1,237.2) 282.9 2,323.8 6.0 17.4 18.7
Balance (in shares) at Dec. 31, 2023     145,164,826 30,778,879          
Increase (Decrease) in Stockholders' Equity                  
Stock options exercised 3.4 3.4     3.4        
Stock options exercised (in shares)     146,765            
Restricted Stock units vested (in shares)     23,051            
Stock based compensation 4.6 4.6     4.6        
Employee stock purchase plan 0.2 0.2     0.2        
Cash dividends declared and paid to common shareholders (7.3) (7.3)       (7.3)      
Loans to noncontrolling interest (0.9)             (0.9)  
Consolidated net (loss) income 52.3 50.9       50.9   1.4 (0.3)
Other comprehensive income (loss) (14.0) (13.7)         (13.7) (0.3) (0.5)
Balance at end of period at Mar. 31, 2024 1,432.9 1,415.3 $ 1.7 $ (1,237.2) 291.1 2,367.4 (7.7) 17.6 17.9
Balance ending (in shares) at Mar. 31, 2024     145,334,642 30,778,879          
Increase (Decrease) in Stockholders' Equity                  
Stock options exercised 0.5 0.5     0.5        
Stock options exercised (in shares)     24,484            
Restricted Stock units vested (0.1) (0.1)     (0.1)        
Restricted Stock units vested (in shares)     1,404            
Stock based compensation 4.8 4.8     4.8        
Employee stock purchase plan 2.1 2.1     2.1        
Employee Stock Purchase Plan (in shares)     31,291            
Public Offering, net of issuance costs of $0.8 million 403.0 403.0 $ 0.1   402.9        
Public Offering, net of issuance costs of $0.8 million, shares     6,000,000            
Cash dividends declared and paid to common shareholders (7.7) (7.7)       (7.7)      
Consolidated net (loss) income 7.9 7.6       7.6   0.3 (0.3)
Other comprehensive income (loss) (36.4) (36.3)         (36.3) (0.1) (0.1)
Balance at end of period at Jun. 30, 2024 $ 1,807.0 $ 1,789.2 $ 1.8 $ (1,237.2) $ 701.3 $ 2,367.3 $ (44.0) $ 17.8 $ 17.5
Balance ending (in shares) at Jun. 30, 2024     151,391,821 30,778,879